Enliven Posts Q3 Loss, $884M Cash and Runway Into 2030 Ahead of ENABLE-2 Launch
ELVN has more than doubled off its 52-week low of $14.785.
Summary
Enliven reported a $27.7 million third-quarter net loss but finished September with $884.4 million in cash and securities, extending its runway into 2030 as it prepares to start the pivotal ENABLE-2 trial before year-end.
Key Events · Earnings and Guidance · ELVN
-
Q3 Loss Widens on Phase 3 Prep
Net loss was $27.7 million, or $0.36 per share, versus $20.1 million a year earlier, as R&D rose to $28.0 million from $18.2 million.
-
Cash Runway Extended Into 2030
Cash, cash equivalents and marketable securities totaled $884.4 million at September 30, 2026, up from $462.6 million at December 31, 2025, funding operations into 2030.
-
ENABLE-2 Design Finalized With FDA
The pivotal Phase 3 will enroll about 450 previously treated CML patients, randomized 1:1 to relcobatinib 80 mg daily or an investigator-selected second-generation TKI, with MMR at Week 24 as the primary endpoint.
-
Trial Start Targeted Before Year-End
Enliven says it remains on track to initiate ENABLE-2 before year-end 2026; the FDA alignment itself was already disclosed on October 7.
Analysis · ELVN · Life Sciences
Financial strength, not the loss, is the quarter's headline: $884.4 million in cash and securities now funds operations into 2030, roughly a year beyond the runway into the first half of 2029 disclosed in the prior 10-Q. For a company spending about $36 million a quarter, that removes any near-term financing need, so shareholders face no dilution overhang while the pivotal ENABLE-2 trial runs. The FDA alignment on ENABLE-2 was already public on October 7; what is new here is the trial's concrete shape (about 450 patients, 1:1 against a second-generation TKI, MMR at Week 24 as the accelerated-approval endpoint) and confirmation that initiation is still expected before year-end 2026. Rising R&D spend ($28.0 million vs $18.2 million) is the expected cost of moving into Phase 3, not a warning.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELVN was trading at $44.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $14.79 to $62.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.